Emerging Biosimilars and the Importance of Identifying Experienced Providers


Sponsored Content

Although biologics and biosimilar drugs only represent 2% of U.S. prescription volume, these naturally sourced medications have recently become the focus of much discussion across healthcare channels. Biologics – often considered specialty drugs – have accounted for as much as 37% of drug spending in a single year. Read more about how Biologics and Biosimilars help fight chronic disease as well as the difference between Generics and Biosimilars.

Related Content
© 2024 MJH Life Sciences

All rights reserved.